Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jul 26, 2018 in Benign prostatic hyperplasia | 0 comments

In a nutshell

This study looked at using a combination of alpha blockers (AB) and phosphodiesterase type 5 inhibitors (PDE5I) to treat lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) symptoms. This study concluded that combination therapy of these drugs could improve symptoms.

Some background

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland. An enlarged prostate can affect bladder function and have a negative impact on quality of life. Treatments for BPH may include medication or surgery. Medications for BPH often result in many side effects while surgery can lead to complications.

AB and PDE5I both relax the muscles in the prostate and the bladder neck, improving urine flow and decreasing bladder blockage. They can be used to treat BPH or LUTS separately or together, in a combination therapy.

Methods & findings

Databases were searched for suitable studies and statistical analyses were performed. Eleven studies were analyzed, making a total of 855 patients. Patients were studied based on prostate size, urine flow and erectile function. Patients in the studies were given either AB alone or AB and PDE5I. The duration treatment ranged from 1-3 months in the different studies.

Patients who received both AB and PDE5I showed bigger improvements in prostate size, urine flow and erectile function than patients who only took AB. This improvement depended on ethnicity, severity of symptoms and how long the patients had been taking the medication.

Common side effects included dizziness, headache, nausea, and vomiting. No serious side effects were observed.

The bottom line

This study concluded that the combination AB and PDE5I therapy showed bigger improvements in prostate size, urine flow and erectile function than AB treatment alone.

The fine print

The authors note that the type of AB and the dose taken differed between the study groups. They also note that the results of the study may be influenced by the patient’s ethnicities, symptoms and duration of treatment. These factors may affect the study’s overall results.

What’s next?

If you are interested in learning more about combination AB and PDE5I treatment for BPH or LUTS, contact your doctor.

Published By :

World Journal of Urology

Date :

Jun 12, 2018

Original Title :

Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.

click here to get personalized updates